Resources

Selected
  • COVID-19
Type of publications
Regions
Diseases
Methodological quality (AMSTAR 2)

1589 results found

2022 ∙ Kroon, F. P. B. Najm, A. Alunno, A. Schoones, J. W. Landewe, R. B. M. Machado, P. M. Navarro-Compan, V.

Risk and prognosis of SARS-CoV-2 infection and vaccination against SARS-CoV-2 in rheumatic and musculoskeletal diseases: a systematic literature review to inform EULAR recommendations

  • All age groups
  • COVID-19
  • Safety
  • Efficacy/effectiveness
Methodological quality (AMSTAR 2):
Low
2022 ∙ Tsiorou, K. Sarantaki, A.

Risk Assessment of COVID-19 Vaccination Among Childbearing Women

  • Adults
  • Adolescents
  • Pregnant women
  • COVID-19
  • Safety
  • Efficacy/effectiveness
Methodological quality (AMSTAR 2):
Critically low
2022 ∙ Petrá M Janovská, D. Čelko, A. M. D Selinger, E. Dole Neradov Franklová, M. Dlouhý, P. Rosina, J. Lesná, I. K.

Risk factors affecting COVID-19 vaccine effectiveness identified from 290 cross-country observational studies until February 2022: a meta-analysis and meta-regression

  • All age groups
  • COVID-19
  • Efficacy/effectiveness
Methodological quality (AMSTAR 2):
Low
2022 ∙ Dzinamarira, Tafadzwa Murewanhema, Grant Chitungo, Itai Ngara, Bernard Nkambule, Sphamandla Josias Madziva, Roda Herrera, Helena Mukwenha, Solomon Cuadros, Diego F. Iradukunda, Patrick Gad Mashora, Moreblessing Tungwarara, Nigel Rwibasira, Gallican Nshogoza Musuka, Godfrey

Risk of mortality in HIV-infected COVID-19 patients: A systematic review and meta-analysis

  • All age groups
  • COVID-19
  • Efficacy/effectiveness
Methodological quality (AMSTAR 2):
Critically low
2022 ∙ Flacco, M. E. Acuti Martellucci, C. Baccolini, V. De Vito, C. Renzi, E. Villari, P. Manzoli, L.

Risk of reinfection and disease after SARS-CoV-2 primary infection: meta-analysis

  • Adults
  • Older adults
  • Adolescents
  • COVID-19
  • Efficacy/effectiveness
Methodological quality (AMSTAR 2):
Critically low
2022 ∙ Chu, D. K. Abrams, E. M. Golden, D. B. K. Blumenthal, K. G. Wolfson, A. R. Stone, C. A., Jr. Krantz, M. S. Shaker, M. Greenhawt, M.

Risk of Second Allergic Reaction to SARS-CoV-2 Vaccines: A Systematic Review and Meta-analysis

  • Adults
  • Older adults
  • COVID-19
  • Safety
Methodological quality (AMSTAR 2):
Critically low
2022 ∙ SeyedAlinaghi, S. Karimi, A. Pashaei, Z. Afzalian, A. Mirzapour, P. Ghorbanzadeh, K. Ghasemzadeh, A. Dashti, M. Nazarian, N. Vahedi, F. Tantuoyir, M. M. Shamsabadi, A. Dadras, O. Mehraeen, E.

Safety and Adverse Events Related to COVID-19 mRNA Vaccines; a Systematic Review

  • Adolescents
  • Adults
  • Older adults
  • COVID-19
  • Safety
Methodological quality (AMSTAR 2):
Critically low
2022 ∙ Dadras, O. Mehraeen, E. Karimi, A. Tantuoyir, M. M. Afzalian, A. Nazarian, N. Mojdeganlou, H. Mirzapour, P. Shamsabadi, A. Dashti, M. Ghasemzadeh, A. Vahedi, F. Shobeiri, P. Pashaei, Z. SeyedAlinaghi, S.

Safety and Adverse Events Related to Inactivated COVID-19 Vaccines and Novavax;a Systematic Review

  • All age groups
  • COVID-19
  • Safety
Methodological quality (AMSTAR 2):
Critically low
2022 ∙ Mehta, N. Shah, S. Paudel, K. Chamlagain, R. Chhetri, S.

Safety and efficacy of coronavirus disease-19 vaccines in chronic kidney disease patients under maintenance hemodialysis: A systematic review

  • Older adults
  • COVID-19
  • Safety
  • Efficacy/effectiveness
Methodological quality (AMSTAR 2):
Critically low
2022 ∙ Tian, F. Yang, R.

Safety and Efficacy of COVID-19 Vaccines in Children and Adolescents: a Systematic Review of Randomized Controlled Trials

  • Newborn
  • Children
  • COVID-19
  • Safety
  • Efficacy/effectiveness
Methodological quality (AMSTAR 2):
Critically low
Loading...